They Were Treating the Symptoms. Nobody Connected the Dots.

PCOS has been renamed — and the new name finally tells the truth about what this condition actually is.

I want to tell you about some of the women I have worked with.

The woman with thinning hair and a type 2 diabetes diagnosis, managing both with medication. Nobody had looked at what the two had in common.

The young woman in her late twenties — persistent acne, one or two ovarian cysts in her history — who had been on Roaccutane and an anti-androgen for years. The skin was being treated. The reason for the skin was not.

The woman who slept with a CPAP machine every night. Her waist circumference told a different story — one that pointed clearly toward non-alcoholic fatty liver disease. Two separate entries on her medical chart. One underlying driver, if you followed the thread.

The slim woman trying to fall pregnant, who had been through years of investigation and had never once had her fasting insulin tested.

The woman with irregular and often absent periods, offered the oral contraceptive pill every time she raised it. Offered it again. And again. Never told what was driving the irregularity in the first place.

And the woman I think about most. Postmenopausal, never able to fall pregnant, never told why. Now managing inflammatory condition after inflammatory condition — each treated separately, each tracing back, if you follow the thread, to the same metabolic pattern that was present in her body decades before anyone named it.

I can see the family patterns too. A mother with one cluster of symptoms. Her daughters with different ones. Different presentations. The same underlying story.

That story just got a new name. And the name matters more than you might expect.

PCOS has been officially renamed PMOS

On 12 May 2026, polycystic ovary syndrome — PCOS — was officially renamed polyendocrine metabolic ovarian syndrome, or PMOS. The announcement was published in The Lancet and presented at the European Congress of Endocrinology in Prague.

This was not a rebrand. It was the conclusion of more than a decade of scientific work — over 22,000 survey responses, 56 international organisations, clinicians and patients from every world region, three years of transition planning. The process was led by Professor Helena Teede at Monash University, with funding from the Australian National Health and Medical Research Council.

The result was unanimous. The old name had to go. Because the old name was causing real harm.

What was wrong with PCOS?

The term polycystic ovary syndrome was inaccurate in almost every part of it.

"Polycystic" implied pathological ovarian cysts. They are not cysts. They are arrested follicles — an important distinction. And up to a quarter of women who have every other feature of this condition show no relevant changes on ultrasound at all. Under the old name, they were excluded from diagnosis entirely.

"Ovarian syndrome" reduced a complex, whole-body condition to a single organ, pointing clinicians toward the ovaries when the actual driver of the condition was systemic.

The consequences were predictable and serious. Care became fragmented. Skin went to one specialist. Fertility to another. Weight was addressed with lifestyle advice that rarely acknowledged the metabolic picture underneath. Mood changes were attributed to stress. And insulin resistance — the central driver, present in approximately 85% of cases — was rarely tested and almost never treated.

"For too long, girls and women have been led to believe this is an ovary problem." — Dr. Elisa Song, Tiny Health CMO, 2026

What the new name actually tells us

PMOS — polyendocrine metabolic ovarian syndrome — unpacks the condition accurately for the first time:

•          Poly-endocrine: Multiple hormonal systems are involved — insulin, androgens, cortisol, and neuroendocrine hormones all interact. This is not one hormone. It is a system-wide pattern.

•          Metabolic: The condition is fundamentally rooted in metabolic dysfunction — particularly insulin resistance and its downstream effects on glucose, fat metabolism, inflammation, and hormonal signalling.

•          Ovarian: The ovaries are affected — but as a consequence of the broader systemic dysfunction, not the primary driver.

•          Syndrome: A cluster of features that manifest differently in different women.

One in eight women worldwide. Approximately 170 million people globally. The most common hormonal and metabolic disorder in women of reproductive age. Forty percent of infertility cases. And the WHO estimates that 70% of those affected have never received a diagnosis.

That is not a testing gap. It is a framework gap. When the framework is wrong, everything built on it is wrong too.

Why this matters for you

If any part of this has felt familiar — if you have recognised a pattern in your own history, or in your daughter's, or in what you have been told over years of managing separate symptoms separately — this is worth understanding fully.

In the weeks ahead I am going to be writing more about what PMOS actually looks like in the body, why so many women were missed, and what a whole-body approach to addressing it actually involves. This is some of the most important clinical territory I work in. I want you to have the full picture.

Subscribe to the Foxy For Life newsletter to make sure you receive each post as it comes out.

Subscribe here →

And if you already want to sit down and look at your own picture properly — a Foundational Health Assessment is where that conversation starts.

Book a Foundational Health Assessment →

Cherice

Frequently Asked Questions

What is PMOS and how is it different from PCOS?

PMOS — polyendocrine metabolic ovarian syndrome — is the new name for what was previously called polycystic ovary syndrome (PCOS). The rename, published in The Lancet in May 2026, reflects the condition's true nature: a whole-body metabolic and multi-hormonal disorder driven primarily by insulin resistance. The name change does not alter the diagnostic criteria — it changes the framework for understanding and treating the condition.

Who does PMOS affect?

PMOS affects an estimated one in eight women worldwide — approximately 170 million people globally. It is the most common hormonal and metabolic disorder in women of reproductive age, and it contributes to nearly 40% of infertility cases worldwide. Critically, the WHO estimates that 70% of those affected have never received a diagnosis.

Why did so many women go undiagnosed under the old name?

The term PCOS directed clinical attention toward the ovaries and toward visible cysts. Up to a quarter of women with the full metabolic and hormonal picture of PMOS show no relevant changes on ovarian ultrasound — meaning they were excluded from diagnosis entirely. The systemic, metabolic nature of the condition was consistently under-recognised.

Does the rename change how PMOS is treated?

The diagnostic criteria remain the same. What the rename signals — and what the emerging clinical consensus supports — is a fundamental shift toward treating the metabolic root of the condition rather than managing individual symptoms. That shift is already underway in how progressive practitioners are approaching care.